AKT1 and hepatocellular carcinoma: Evidence suggests EGCG can directly or indirectly target ERα36 in hepatoma cells, thus downregulating EGFR and HER2, as well as blocking PI3K/Akt and mitogen-activated protein kinases (MAPK)/ERK pathways (Chen et al., 2019).